

Exosomal long noncoding RNA *LNMAT2* promotes lymphatic metastasis in bladder cancer


Changhao Chen, ... , Rufu Chen, Tianxin Lin

J Clin Invest. 2020;130(1):404-421. <https://doi.org/10.1172/JCI130892>.

Research Article

Oncology

Graphical abstract



Find the latest version:

<https://jci.me/130892/pdf>



Exosomal long noncoding RNA *LNMAT2* promotes lymphatic metastasis in bladder cancer

Changhao Chen,^{1,2} Yuming Luo,^{2,3} Wang He,^{1,2} Yue Zhao,⁴ Yao Kong,⁵ Hongwei Liu,^{1,2} Guangzheng Zhong,^{1,2} Yuting Li,⁶ Jun Li,⁷ Jian Huang,^{1,2} Rufu Chen,⁸ and Tianxin Lin^{1,2}

¹Department of Urology, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China. ²Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, State Key Laboratory of Oncology in South China, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China. ³Department of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China. ⁴Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. ⁵Department of Ultrasound and ⁶Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China. ⁷Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China. ⁸Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.

Patients with bladder cancer (BCa) with clinical lymph node (LN) metastasis have an extremely poor prognosis. VEGF-C has been demonstrated to play vital roles in LN metastasis in BCa. However, approximately 20% of BCa with LN metastasis exhibits low VEGF-C expression, suggesting a VEGF-C-independent mechanism for LN metastasis of BCa. Herein, we demonstrate that BCa cell-secreted exosome-mediated lymphangiogenesis promoted LN metastasis in BCa in a VEGF-C-independent manner. We identified an exosomal long noncoding RNA (lncRNA), termed lymph node metastasis-associated transcript 2 (*LNMAT2*), that stimulated human lymphatic endothelial cell (HLEC) tube formation and migration in vitro and enhanced tumor lymphangiogenesis and LN metastasis in vivo. Mechanistically, *LNMAT2* was loaded to BCa cell-secreted exosomes by directly interacting with heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1). Subsequently, exosomal *LNMAT2* was internalized by HLECs and epigenetically upregulated prospero homeobox 1 (*PROX1*) expression by recruitment of hnRNPA2B1 and increasing the H3K4 trimethylation level in the *PROX1* promoter, ultimately resulting in lymphangiogenesis and lymphatic metastasis. Therefore, our findings highlight a VEGF-C-independent mechanism of exosomal lncRNA-mediated LN metastasis and identify *LNMAT2* as a therapeutic target for LN metastasis in BCa.

Introduction

Bladder cancer (BCa), one of the most commonly diagnosed malignancies worldwide, is the leading cause of cancer-related death among men, with an estimated 550,000 new cases and 20,000 deaths in 2018 (1). The prognosis of patients with BCa is closely associated with the presence of lymph node (LN) metastasis, which decreases the 5-year survival rate from 77.6% to 18.6% (2). Despite the overwhelming evidence for the role of LN metastasis in cancer, the definite molecular mechanism that triggers it in BCa remains unclear. We have previously demonstrated that VEGF-C produced by tumor cells (3) and tumor-associated macrophages (TAMs) (4) plays a crucial role in BCa lymphangiogenesis and LN metastasis. However, approximately 20% of BCa with LN metastasis has low VEGF-C expression (5, 6), which suggests the existence of a VEGF-C-independent mechanism for lymphangiogenesis and LN metastasis in BCa.

Prospero homeobox 1 (*PROX1*) is essential for lymphatic vascular system formation, regulating endothelial cell differentiation and inducing the lymphatic budding and extension of lymphatic endothelial cells (7, 8). *Prox1*^{-/-} mice lack a lymphatic vascular sys-

tem and die within a few days of birth (9). *PROX1* enhanced lymphatic endothelial cell proliferation through synergistic interaction with p50 to activate VEGFR3 expression (10). Nevertheless, the precise mechanism of cancer cell promotion of lymphangiogenesis and *PROX1* upregulation remains unclear.

Exosomes are small microvesicles ranging from 30–150 nm in size that contain various types of nucleic acids, including mRNAs, miRNAs, and long noncoding RNAs (lncRNAs) (11, 12). Recently, cancer cell-secreted exosomes were identified as crucial messengers in intercellular communication associated with cancer-induced vascular permeability (13), inflammation (14), and bone marrow progenitor cell recruitment in distant organs (15). For example, EGFR-containing exosomes regulate the liver microenvironment to promote liver metastasis (16), exosomal *miR-25-3p* participates in premetastatic niche formation (17), and exosomal *miR-1247-3p* facilitates lung metastasis by activating cancer-associated fibroblasts (18). However, the mechanism of cancer cell-secreted exosome regulation of lymphatic vascular system formation via the induction of lymphangiogenesis remains unknown, warranting further exploration.

Herein, we report that an lncRNA, *LINC00858*, termed lymph node metastasis-associated transcript 2 (*LNMAT2*), was overexpressed in BCa tissues and highly enriched in urinary exosomes (urinary-EXO) from patients with BCa, and correlated positively with LN metastasis. Exosomal *LNMAT2* promoted lymphangiogenesis and LN metastasis in vitro and in vivo. Mechanistically, *LNMAT2* was loaded to exosomes by direct interaction with heterogeneous

Authorship note: CC, Y. Luo, WH, and YZ contributed equally to this study.

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2020, American Society for Clinical Investigation.

Submitted: June 6, 2019; **Accepted:** October 2, 2019; **Published:** December 3, 2019.

Reference information: J Clin Invest. 2020;130(1):404–421.

<https://doi.org/10.1172/JCI130892>.




Figure 1. *LNMAT2* overexpression is associated with BCa lymphatic metastasis. (A) qRT-PCR analysis of *LNMAT2* expression in a cohort of 266 BCa patients according to LN status. Groups were compared using the nonparametric Mann-Whitney *U* test. *GAPDH* was used as an internal control. The OS (B) and DFS (C) of patients with BCa with lower vs. higher *LNMAT2* expression were estimated using Kaplan-Meier curves. The median expression was used as the cut-off value. Representative ISH images (D) and percentages (E) of *LNMAT2* expression (blue) in paraffin-embedded NAT and BCa tissue with or without LN metastasis ($n = 266$). Scale bars: 50 μ m. Statistical significance was assessed by χ^2 test. Representative images (F) and correlation analysis (G and H) of ISH and IHC staining showing positive correlation between *LNMAT2* expression and lymphatic vessel density indicated by anti-LYVE-1 staining, and that *LNMAT2* expression was not correlated with VEGF-C levels in the BCa tissues ($n = 266$). Scale bars: 50 μ m. * $P < 0.05$; ** $P < 0.01$.

nuclear ribonucleoprotein A2B1 (hnRNP A2B1) and transmitted to human lymphatic endothelial cells (HLECs). Subsequently, *LNMAT2* formed a triplex with the *PROX1* promoter and enhanced *PROX1* transcription by inducing hnRNP A2B1-mediated H3 lysine 4 trimethylation (H3K4me3), facilitating lymphangiogenesis and LN metastasis in BCa. Our findings highlight a VEGF-C-independent mechanism of exosomal *LNMAT2*-mediated LN metastasis and identify *LNMAT2* as a potential diagnostic marker and therapeutic target for LN metastasis in BCa.

Results

***LNMAT2* overexpression correlated with BCa LN metastasis.** Using next-generation sequencing (NGS), we previously explored the global expression profiles of lncRNAs in high-grade muscle-invasive bladder cancer (MIBC) tissues and paired normal adjacent tissues (NATs) from 5 patients with BCa and in 5 paired LN-positive and LN-negative BCa tissues (4) (Gene Expression Omnibus ID GSE106534). Statistical analysis revealed that *LNMAT2* expression was increased by more than 3-fold in the

MIBC tissues compared with the NATs and in the LN-positive BCa tissues compared with the LN-negative tissues. Quantitative real-time PCR (qRT-PCR) confirmed *LNMAT2* overexpression in BCa tissues from 266 patients compared with the corresponding NATs (Supplemental Figure 1A; supplemental material available online with this article; <https://doi.org/10.1172/JCI130892DS1>). In humans, *LNMAT2* is located on chromosome 10q23.1 (Ref-Seq accession number MK692948, Supplemental Figure 1B), and the full-length 3187 nt *LNMAT2* in BCa cells was determined by 5' and 3' rapid amplification of cDNA ends (RACE) assays (Supplemental Figure 1, C–F). FISH and subcellular fractionation assays showed that *LNMAT2* mainly localized to BCa cell cytoplasm (Supplemental Figure 2, A–D). Consistently, analyses of The Cancer Genome Atlas (TCGA) database showed that *LNMAT2* was upregulated in multiple human cancers, such as BCa, uterine corpus endometrial cancer, lung cancer, liver cancer, and stomach cancer (Supplemental Figure 3, A–F).

Moreover, a positive correlation was found between *LNMAT2* expression and LN metastasis in a cohort of 266 BCa patients (Figure 1A and Supplemental Table 1). qRT-PCR detected higher *LNMAT2* expression in metastatic tumor cells in the LNs than in BCa primary tumors, suggesting that *LNMAT2* might contribute to BCa metastasis (Supplemental Figure 4A). Furthermore, Kaplan-Meier analysis revealed that *LNMAT2* overexpression correlated with shorter overall survival (OS) and disease-free survival (DFS) in BCa patients (Figure 1, B and C). Univariate and multivariate Cox analysis confirmed that *LNMAT2* expression correlated independently with OS and DFS in BCa patients (Supplemental Tables 2 and 3). Consistently, the TCGA database results indicated a positive association between *LNMAT2* overexpression and poor prognosis in human cancer, including lung cancer and stomach cancer (Supplemental Figure 4, B–D). It is worth noting that *LNMAT2* overexpression was highly correlated with reduced OS and DFS in LN-positive BCa patients (Supplemental Figure 4, E and F). *LNMAT2* expression was significantly upregulated in the LN-positive BCa tissues, slightly increased in LN-negative BCa tissues, and was rarely detected in NATs by in situ hybridization (ISH) assay (Figure 1, D and E, and Supplemental Figure 4G). Importantly, *LNMAT2* expression was also positively correlated with lymphatic vessel density, as indicated by the specific lymphatic vessel marker lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), but no correlation was observed between *LNMAT2* and VEGF-C expression in BCa (Figure 1, F–H). Collectively, these results indicate that *LNMAT2* overexpression-induced LN metastasis of BCa might be independent of VEGF-C.

LNMAT2 was enriched in BCa cell-secreted exosomes. Prominently, ISH showed high *LNMAT2* expression in the extracellular space of BCa (Figure 1D). We also found significantly higher extracellular *LNMAT2* expression in BCa tissues with LN metastasis compared with BCa tissues without LN metastasis (Figure 1, D and E), suggesting that extracellular *LNMAT2* might play a crucial role in BCa LN metastasis. As extracellular lncRNAs are mainly encapsulated in specific subcellular materials, exosomes in particular, and have important biological functions in mediating cell-cell interactions and contributing to tumor LN metastasis (19), we examined *LNMAT2* expression in BCa cell-secreted

exosomes. We used qRT-PCR to analyze the exosomes isolated from the urine samples of 206 patients with BCa and 120 healthy controls and found that *LNMAT2* was upregulated in the urinary-EXO obtained from BCa patients compared with the healthy controls (Figure 2A), suggesting that exosomal *LNMAT2* is essential to the development of BCa.

We further examined *LNMAT2* expression in exosomes isolated from the culture medium of BCa cell lines (5637 and UM-UC-3). Exosomes with a typical cup-shaped morphology and 30–150 nm in size were detected by transmission electron microscopy (TEM) (Figure 2B and Supplemental Figure 4H) and NanoSight analysis (Figure 2C and Supplemental Figure 4I). Western blot detection of the exosomal protein markers CD9 and CD63 confirmed that the particles isolated from the culture medium were exosomes (Figure 2D and Supplemental Figure 4J). *LNMAT2* expression was significantly upregulated in both the 5637 and UM-UC-3 cells and their corresponding exosomes as compared with that in human normal bladder epithelial cells (SV-HUC-1) (Figure 2E). Interestingly, *LNMAT2* enrichment was detected in BCa cell-secreted exosomes relative to its expression in the cells, suggesting that *LNMAT2* may exert its main function in exosomal form (Figure 2E). *LNMAT2* overexpression via *LNMAT2* plasmid transfection led to an obvious increase of *LNMAT2* levels in the BCa cell-secreted exosomes (Figure 2, F and G), while silencing *LNMAT2* had the opposite effect (Figure 2, H and I), suggesting that altering cellular *LNMAT2* expression markedly impacts exosomal *LNMAT2* expression, solidifying our hypothesis that extracellular *LNMAT2* exists mainly in exosomal form. Taken together, our results indicate that *LNMAT2* is abundant in BCa cell-secreted exosomes.

BCa cell-secreted exosomal LNMAT2 promoted lymphangiogenesis in vitro. Since lymphangiogenesis is the rate-determining step for LN metastasis in BCa (20), we investigated whether upregulating *LNMAT2* expression could facilitate lymphangiogenesis in vitro. The tube formation and migration in HLECs incubated with BCa cell-secreted exosomes were analyzed. The BCa cell-secreted exosomes dramatically promoted HLEC tube formation and migration as compared with the control (Figure 3, A–C). Moreover, the exosomes secreted by *LNMAT2*-overexpressing UM-UC-3 cells (UM-UC-3-EXO_{*LNMAT2*}) strongly induced HLEC tube formation and migration (Figure 3, D–F). Conversely, exosomes secreted by *LNMAT2*-silenced 5637 cells (5637-EXO_{si-*LNMAT2*}) lost the ability to induce HLEC tube formation and migration (Figure 3, G–I). These results indicate that exosomal *LNMAT2* contributes to lymphangiogenesis in vitro.

Exosomal LNMAT2 promoted lymphatic metastasis in vivo. Although we observed that *LNMAT2* knockdown led to a reduction and *LNMAT2* overexpression led to an increase in the growth rates of BCa cells, as indicated by CCK-8, colony formation, and EdU assays (Supplemental Figure 5, A–H), dysregulation of *LNMAT2* has no obvious effect on the invasiveness of BCa cells, which provided further evidence that exosomal *LNMAT2* plays vital roles in LN metastasis.

To further examine the effect of exosomal *LNMAT2* on LN metastasis, we established a popliteal lymphatic metastasis model using similar modeling approaches as described previously (4, 21). Luciferase-labeled UM-UC-3 cells were implanted in the




Figure 2. *LNMAT2* is upregulated in BCa cell-secreted exosomes. (A) qRT-PCR analysis of *LNMAT2* expression in urinary-EXO from 206 patients with BCa and 120 healthy participants. *GAPDH* was used as an internal control. Groups were compared using the nonparametric Mann-Whitney *U* test. Purified 5637-EXO was identified by TEM (B) and NanoSight (C). Scale bars: 100 nm. (D) Western blot analysis of exosomal protein markers in 5637 cell lysates or 5637-EXO. (E) qRT-PCR analysis of *LNMAT2* expression levels in bladder cell lines and in their corresponding exosomes. *GAPDH* was used as an internal control. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. qRT-PCR analysis of *LNMAT2* expression in *LNMAT2*-over-expressing control BCa cells (F) and their corresponding exosomes (G). *GAPDH* was used as an internal control. Statistical significance was assessed using 2-tailed Student's *t* test followed by Dunnett's tests for multiple comparisons. qRT-PCR detection of *LNMAT2* expression in *LNMAT2* knockdown control BCa cells (H) and their corresponding exosomes (I). *GAPDH* was used as an internal control. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests for multiple comparisons. Error bars represent the SD of 3 independent experiments. **P* < 0.05; ***P* < 0.01.

footpads of nude mice, which were then randomly divided into 3 groups (*n* = 12), followed by intratumoral injection with PBS (control), exosomes secreted by vector-transfected UM-UC-3 cells (UM-UC-3-EXO_{Vector}), or exosomes secreted by *LNMAT2*-transfected UM-UC-3 cells (UM-UC-3-EXO_{*LNMAT2*}) every 3 days. When the primary tumor reached 200 mm³, the tumors and popliteal LNs were excised (Figure 4A). Interestingly, the live IVIS Spectrum In Vivo Imaging System showed that UM-UC-3-EXO_{*LNMAT2*}

significantly promoted the ability of BCa cells to metastasize to the LNs as compared with the control or UM-UC-3-EXO_{Vector} groups (Figure 4, B and C). The volume of popliteal LNs in the UM-UC-3-EXO_{*LNMAT2*} group was significantly larger than that in the control or UM-UC-3-EXO_{Vector} groups (Figure 4, D and E). Luciferase immunostaining indicated increased metastatic LNs in the UM-UC-3-EXO_{*LNMAT2*} group, which confirmed that exosomal *LNMAT2* significantly enhanced the metastatic capability of BCa




Figure 3. Exosomal *LNMAT2* promotes lymphangiogenesis in vitro. Representative images (A) and quantification of tube formation (B) and Transwell migration (C) by HLECs treated with PBS, 5637-EXO, or UM-UC-3-EXO. Scale bars: 100 μ m. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. Representative images (D) and quantification of tube formation (E) and Transwell migration (F) by HLECs treated with UM-UC-3-EXO_{Vector} or UM-UC-3-EXO_{LNMAT2}. Scale bars: 100 μ m. Statistical significance was assessed using 2-tailed Student's *t* test. Representative images (G) and quantification of tube formation (H) and Transwell migration (I) by HLECs treated with 5637-EXO_{si-NC}, 5637-EXO_{si-LNMAT2#1}, or 5637-EXO_{si-LNMAT2#2}. Scale bars: 100 μ m. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. Error bars represent the SD of 3 independent experiments. **P* < 0.05; ***P* < 0.01.

cells (Figure 4, F and G, and Supplemental Table 4). Taken together, these results suggest that exosomal *LNMAT2* plays an important part in LN metastasis of BCa in vivo.

Tumorigenicity is a major factor underlying lymphangiogenesis and LN metastasis (22), and is closely associated with LN involvement in various solid tumors, such as lung cancer (23), gastric cancer (24), and appendix neuroendocrine tumor (25). Therefore, we investigated the tumorigenic capacity of exosomal *LNMAT2* in vivo using

a subcutaneous xenograft model as previously reported (3, 21). Mice were inoculated subcutaneously with UM-UC-3 cells and randomly separated into 3 groups (*n* = 12). Each group received intratumoral PBS, UM-UC-3-EXO_{Vector}, or UM-UC-3-EXO_{LNMAT2} every 3 days for 5 consecutive weeks (Figure 5A). UM-UC-3-EXO_{LNMAT2} enhanced tumor growth compared with both the UM-UC-3-EXO_{Vector} group and the control group (Figure 5, B–D). Tumors in the UM-UC-3-EXO_{LNMAT2} group were of greater size and weight (Figure 5, E and F) and had




Figure 4. Exosomal *LNMT2* promotes lymphatic metastasis in vivo. (A) Schematic representation of establishment of the nude mouse model of popliteal LN metastasis. Representative bioluminescence images (B) and histogram analysis (C) of popliteal metastatic LN from nude mice treated with PBS, UM-UC-3-EXO_{Vector} or UM-UC-3-EXO_{LNMT2} after UM-UC-3 cells had been inoculated into the footpad ($n = 12$). Red arrow indicates footpad tumor and metastatic popliteal LN. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (D) Representative image of the popliteal LN metastasis model. (E) Representative images of enucleated popliteal LNs (left) and histogram analysis (right) of the LN volume of all groups ($n = 12$). Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (F) Representative images of IHC staining with anti-luciferase antibody ($n = 12$). Scale bars: 500 μ m (red) or 50 μ m (black). (G) Percentages of LN status in all groups ($n = 12$). Statistical significance was assessed by χ^2 test. Error bars represent the SD of 3 independent experiments. * $P < 0.05$; ** $P < 0.01$.




Figure 5. Exosomal *LNMT2* promotes BCa tumorigenesis in vivo. (A) Schematic representation of the establishment of the xenograft model. Representative bioluminescence images (B) and histogram analysis (C) of subcutaneous tumors from nude mice treated with PBS, UM-UC-3-EXO_{Vector}, or UM-UC-3-EXO_{LNMT2} ($n = 12$). Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (D) Representative images of gross appearance of subcutaneous tumors from nude mice treated with PBS, UM-UC-3-EXO_{Vector}, or UM-UC-3-EXO_{LNMT2} ($n = 12$). Measured tumor volumes (E) and weights (F) ($n = 12$). Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. Representative images (G) and histogram analysis (H) of IHC staining for Ki67 expression ($n = 12$). Scale bars: 50 μ m. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. Error bars represent the SD of 3 independent experiments. * $P < 0.05$; ** $P < 0.01$.

higher expression levels of the proliferation marker Ki67 as compared with the UM-UC-3-EXO_{vector} and control groups (Figure 5, G and H). Collectively, these results indicate that BCa cell-secreted exosomal *LNMAT2* can promote lymphangiogenesis and LN metastasis in vivo.

LNMAT2 interacted directly with hnRNPA2B1. Next, we investigated the molecular mechanism and interacting partners of *LNMAT2* in BCa. In vitro RNA pull-down assays with biotinylated *LNMAT2* and antisense control showed an obvious 35–40 kDa band (Figure 6A), which mass spectrometry (MS) confirmed was hnRNPA2B1 (Figure 6B). Western blot analysis of *LNMAT2*-enriched proteins after RNA pull-down indicated that *LNMAT2* bound specifically to hnRNPA2B1 (Figure 6, C and D). Consistently, confocal microscopy of *LNMAT2* FISH and hnRNPA2B1 immunostaining showed that *LNMAT2* and hnRNPA2B1 colocalized mostly in the cytoplasm of BCa cells (Figure 6E). RNA immunoprecipitation (RIP) showed enrichment of *LNMAT2* by hnRNPA2B1, validating the interaction between *LNMAT2* and hnRNPA2B1 (Figure 6F and Supplemental Figure 6A). Moreover, serial deletion analysis determined that the 1900–2100 nt region of *LNMAT2* was indispensable for direct interaction with hnRNPA2B1 (Figure 6, G and H). hnRNPA2B1, an RNA-binding protein (RBP), is involved in cytoplasmic RNA trafficking through the recognition of specific sequences on the target RNA (26). Sequence analysis by POSTAR2 (27, 28) indicated a sequence motif and structural preference of the RBP binding site for hnRNPA2B1 (Figure 6I), which was located in the 1930–1960 nt region of *LNMAT2* and formed a stem-loop structure (Figure 6J). RIP performed after site-directed mutagenesis of this region revealed that it was critical to *LNMAT2* interaction with hnRNPA2B1 (Figure 6K and Supplemental Figure 6B).

hnRNPA2B1 mediated LNMAT2 packaging into exosomes. RNAs are selectively loaded into exosomes by RBPs (29, 30), including hnRNPA2B1. Accordingly, we examined whether the direct interaction of *LNMAT2* with hnRNPA2B1 contributed to the packaging of *LNMAT2* into exosomes. As shown in Figure 7A and Supplemental Figure 6C, hnRNPA2B1 knockdown reduced *LNMAT2* levels only in the exosomes secreted by BCa cells but had no effect on *LNMAT2* expression in BCa cells. hnRNPA2B1 sorts RNAs into exosomes by recognizing a specific motif (i.e., GGAG) (29), which is present on the hnRNPA2B1 binding sites (1930–1960 nt) of *LNMAT2*. Therefore, we induced mutation at these sites and observed significantly decreased BCa cell production of exosomal *LNMAT2*, indicating that the interaction between hnRNPA2B1 and these binding sites is important for *LNMAT2* packaging into exosomes (Figure 7B and Supplemental Figure 6D). Additionally, in comparison with *miR-18a*, an miRNA retained in cells rather than loaded into exosomes (29), *LNMAT2* presented a much higher exosome-to-cell ratio (Figure 7C and Supplemental Figure 6E), which is similar to the report by Villarroja-Beltri et al., who demonstrated hnRNPA2B1-mediated exosome packaging of *miR-198* (29). Moreover, hnRNPA2B1 knockdown significantly decreased the enrichment of *LNMAT2* and *miR-198* in BCa cell-secreted exosomes (Figure 7D and Supplemental Figure 6F), indicating that *LNMAT2* is specifically sorted into exosomes in an hnRNPA2B1-dependent manner.

Exosomal LNMAT2 was internalized by HLECs to induce lymphangiogenesis. As our results indicated that BCa cell-secreted exosomes promoted lymphangiogenesis, we then evaluated the inter-

nalization of exosomes by HLECs. We labeled purified exosomes with PKH67 green fluorescent dye and incubated them with HLECs for 12 hours. Confocal images showed the green fluorescent punctate signal in the cytoplasm of recipient HLECs, indicating internalization of the PKH67-labeled exosomes, whereas no PKH67 fluorescent signal was observed in the control group, suggesting that the HLECs internalized the BCa cell-secreted exosomes (Figure 7E). We further examined whether exosomal *LNMAT2* was successfully transferred into the HLECs and found that *LNMAT2* expression was significantly increased in the HLECs after incubation with the exosomes (Figure 7F). Furthermore, *LNMAT2* knockdown in exosomes secreted by 5637 cells diminished their ability to induce *LNMAT2* overexpression (Figure 7G), whereas UM-UC-3-EXO_{LNMAT2} increased *LNMAT2* expression significantly in the HLECs (Supplemental Figure 7A).

To exclude the possibility that transcriptional activation of endogenous *LNMAT2* in the HLECs activated the lymphangiogenesis, we established *LNMAT2*-KO cells from HLECs using the CRISPR-Cas9 approach with paired sgRNAs specifically targeting *LNMAT2* (Supplemental Figure 7B). *LNMAT2* deficiency was subsequently detected in the KO cells, suggesting successful inhibition of endogenous *LNMAT2* expression (Figure 7H). We then evaluated the effects of exosomal *LNMAT2* on *LNMAT2*-WT and *LNMAT2*-KO HLECs. Tube formation and Transwell assays both demonstrated that, compared with exosomes secreted by si-NC-transfected 5637 cells (5637-EXO_{si-NC}), exosomes secreted by si-*LNMAT2*#1-transfected 5637 cells (5637-EXO_{si-LNMAT2#1}) decreased *LNMAT2*-KO HLEC proliferation and migration (Figure 7, I–K), whereas UM-UC-3-EXO_{LNMAT2} had a promoting effect on *LNMAT2*-KO HLECs as compared with UM-UC-3-EXO_{vector} (Supplemental Figure 7, C–E). These results were in accordance with those for the *LNMAT2*-WT HLECs (Figure 7, I–K and Supplemental Figure 7, C–E). Taken together, the results indicate that BCa cells induce lymphangiogenesis by transmitting exosomal *LNMAT2* to HLECs.

Exosomal LNMAT2 upregulated PROX1 expression independent of VEGF-C. Previously, we demonstrated that VEGF-C produced by tumor cells (3) and TAMs (4) contributes to lymphangiogenesis and LN metastasis in BCa. However, more than 20% of BCa with LN metastasis presents with low VEGF-C expression (5). Our results showed that neither *LNMAT2* overexpression nor *LNMAT2* knockdown in both 5637 and UM-UC-3 cells induced VEGF-C mRNA or protein changes (Supplemental Figure 8, A–D), which suggested that exosomal *LNMAT2*-induced lymphangiogenesis and LN metastasis in BCa might be through a VEGF-C-independent mechanism.

It has been proposed that PROX1 is essential for lymphatic vascular system development by regulating endothelial cell differentiation and metastatic dissemination (31, 32). Interestingly, qRT-PCR and Western blot analyses showed that PROX1 expression was significantly increased in exosomal *LNMAT2*-treated HLECs as compared with the control-treated HLECs (Figure 8, A and B, and Supplemental Figure 8, E and F), indicating that exosomal *LNMAT2* upregulated PROX1 expression in HLECs.

Exosomal LNMAT2 formed a DNA-RNA triplex with the PROX1 promoter. To investigate the molecular mechanisms underlying exosomal *LNMAT2*-induced PROX1 expression in HLECs, we ana-




Figure 6. Direct interaction of *LNMAT2* with *hnRNPA2B1*. (A) RNA pull-down assay using *LNMAT2* sense and antisense RNAs in 5637 cells, followed by silver staining. Red arrows indicate *hnRNPA2B1*. (B) MS identification of *LNMAT2*-binding proteins. RNA pull-down and Western blot with 5637 cell nuclear extract (C) or purified recombinant *hnRNPA2B1* (D) confirmed that *LNMAT2* was associated with *hnRNPA2B1*. (E) Fluorescence assessment of *LNMAT2* and *hnRNPA2B1* colocalization in 5637 cells. Scale bar: 5 μ m. (F) RIP analysis using the anti-*hnRNPA2B1* antibody revealing that *LNMAT2* interacted with *hnRNPA2B1* in 5637 cells. Negative control, IgG; nonspecific control, *U1*. Statistical significance was assessed using 2-tailed Student's *t* test. (G and H) Serial deletions of *LNMAT2* were used in RNA pull-down assays to identify regions required for *LNMAT2* and *hnRNPA2B1* interaction. (I) POSTAR2 prediction of sequence motifs of *hnRNPA2B1* binding sites. (J) RNAfold predicted that *LNMAT2* would have 4 stable stem-loop structures. The inset (framed in red) indicates the *hnRNPA2B1* binding stem-loop structures in *LNMAT2*. (K) RIP assays performed after site-directed mutagenesis of 1930–1960 nt of *LNMAT2* in 5637 cells. Statistical significance was assessed using 2-tailed Student's *t* test. Error bars represent the SD of 3 independent experiments. **P* < 0.05; ***P* < 0.01.

lyzed the subcellular location of exosomal *LNMAT2* after internalization by *LNMAT2*-KO HLECs. Abundant *LNMAT2* was detected in the nucleus (Supplemental Figure 8, G and H), indicating that *LNMAT2* released by BCa cell-secreted exosomes translocated into the HLEC nucleus and exerted essential functions. We generated a series of luciferase constructs containing various lengths of the *PROX1* promoter sequences, which is located from –2000 bp upstream to +200 bp downstream of the transcriptional start site to explore whether exosomal *LNMAT2* transcriptionally upregulated *PROX1*. Luciferase assays showed that the –650 bp to –350 bp region of *PROX1* promoter led to an obvious increase of transcriptional activity in exosomal *LNMAT2*-induced HLECs (Figure 8C and Supplemental Figure 9A). Moreover, chromatin isolation by RNA purification (ChIRP) assays demonstrated that exosomal *LNMAT2* interacted physiologically with the P3 (–607 bp to –597 bp) region in the *PROX1* promoter in HLECs (Figure 8, D–F).

To further investigate whether *LNMAT2* directly interacted with *PROX1* promoter, we obtained 5 potential pairs of triplex-forming oligonucleotides (TFOs) and their corresponding triplex target sites (TTSs) in the exosomal *LNMAT2* and *PROX1* promoter from LongTarget (33), a tool for predicting lncRNA-DNA binding motifs, and each binding motif was subjected to fluorescence resonance energy transfer (FRET) analysis and circular dichroism (CD) spectroscopy (Supplemental Table 5). As shown in Figure 8G and Supplemental Figure 9B, in comparison with the single-stranded RNA (ssRNA)/*PROX1* NC group, the fluorescence signal was markedly increased at 570–580 nm and reduced at 520 nm in the *LNMAT2* (+2058 to +2069 nt)/*PROX1* TTS1 (–607 to –597 bp) group in FRET analysis. These results were in accordance with the *FENDRR/PITX2* positive control group (Supplemental Figure 9C and ref. 34), indicating energy transfer from the fluorescein donor to the rhodamine acceptor, and supporting the formation of a triplex structure (4). CD spectroscopy demonstrated a strong positive peak at 270–280 nm; a deep negative peak at 210 nm was recorded in the *LNMAT2* (+2058 to +2069 nt)/*PROX1* TTS1 (–607 to –597 bp) group (Figure 8H and Supplemental Figure 9D), which was in accordance with the *FENDRR/PITX2* positive control group (Supplemental Figure 9E). This validated the

premise that the triplex was constructed between *LNMAT2* and the *PROX1* promoter sequences in vitro. Additionally, exosomal *LNMAT2* enhanced the luciferase intensity of the *PROX1* promoter, while no obvious change was observed in the mutated *PROX1* promoter (*PROX1*-P3), suggesting that the sequence between –607 and –597 bp in the *PROX1* promoter is of great significance for exosomal *LNMAT2*-induced *PROX1* transactivation (Figure 8, I and J, and Supplemental Figure 9, F and G). Together, these data suggest that exosomal *LNMAT2* can form a triplex with the lymphatic *PROX1* promoter sequence and upregulate its transcription levels.

Exosomal LNMAT2 interacted with hnRNPA2B1 to promote H3K4 trimethylation at the PROX1 promoter. *hnRNPA2B1* is involved in H3K4 trimethylation-associated (H3K4me3-associated) epigenetic regulation by binding to the target DNA (35, 36). Accordingly, we explored whether *hnRNPA2B1* contributes to exosomal *LNMAT2*-induced transactivation of *PROX1* by regulating H3K4me3 levels in the *PROX1* promoter region in HLECs. ChIP indicated enrichment of the *PROX1* promoter sequences associated with *hnRNPA2B1* and H3K4me3 in HLECs treated with exosomes secreted by *LNMAT2*-transfected 5637 cells (5637-EXO_{*LNMAT2*}) and UM-UC-3-EXO_{*LNMAT2*} (Figure 8, K and L, and Supplemental Figure 9, H and I), whereas there was a significant reduction in *PROX1* promoter sequences associated with *hnRNPA2B1* and H3K4me3 in HLECs treated with 5637-EXO_{si-*LNMAT2*#1} (Figure 8, M and N), suggesting that exosomal *LNMAT2* upregulates *PROX1* expression by interacting directly with *hnRNPA2B1* to increase H3K4me3 levels in the *PROX1* promoter.

Exosomal LNMAT2-induced PROX1 upregulation promoted lymphatic metastasis. Next, we clarified whether *PROX1* is required for exosomal *LNMAT2*-induced lymphangiogenesis in BCa. Reducing *LNMAT2* expression in exosomes diminished tumor-induced HLEC proliferation and migration, and ectopic *PROX1* rescued the effects (Figure 9, A–C). In contrast, *PROX1* silencing abolished exosomal *LNMAT2*-induced HLEC tube formation and migration significantly and independently of VEGF-C (Supplemental Figure 10, A and B). These results suggested that *PROX1* was required for exosomal *LNMAT2*-mediated VEGF-C-independent lymphangiogenesis and lymphatic metastasis in vitro. Furthermore, in vivo assays showed that the UM-UC-3-EXO_{*LNMAT2*} group exhibited larger-volume popliteal LNs relative to the UM-UC-3-EXO_{Vector} group after both had been treated with VEGF-C-neutralizing antibody (pV1006R-r) (Figure 9, D–F). IHC of mouse BCa tissues also demonstrated that high *LNMAT2* levels were accompanied by increased *PROX1* expression in LYVE-1-positive lymphatic vessels in both the intratumoral and peritumoral regions (Figure 9, G–I). The UM-UC-3-EXO_{*LNMAT2*} group showed more enhancing effects on LN metastasis relative to the UM-UC-3-EXO_{Vector} group after pV1006R-r treatment in both, resulting in shorter survival times (Figure 9, J and K, and Supplemental Table 6). These results provide further evidence that exosomal *LNMAT2* upregulates *PROX1* expression to induce BCa lymphatic metastasis in a VEGF-C-independent manner.

Exosomal LNMAT2 was associated with LN metastasis in BCa patients. Accumulating evidence shows that BCa cell-secreted exosomal lncRNAs can be detected in urine, and these urinary exosomal lncRNAs have been recognized as promising biomarkers for early diagnosis of BCa (37). Therefore, clarifying the clinical




Figure 7. *LNMAT2* is packaged into exosomes in an hnRNA2B1-dependent manner and transported to HLECs. (A) qRT-PCR analysis of *LNMAT2* expression in exosomes secreted by hnRNA2B1 knockdown cells. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (B) qRT-PCR analysis of *LNMAT2* expression in BCa cell-secreted exosomes. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (C) The exosome/cell ratio of RNAs in 5637 cells obtained by qRT-PCR. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (D) qRT-PCR analysis of RNA levels in exosomes secreted by hnRNA2B1 knockdown 5637 cells. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (E) Schematic illustration of exosome internalization assays and representative images of HLEC fluorescence after incubation with PKH67-labeled (green) BCa cell exosomes. Scale bar: 5 μ m. qRT-PCR analysis of *LNMAT2* expression in HLECs treated with PBS, 5637-EXO, UM-UC-3-EXO (F) or 5637-EXO_{si-NC}, 5637-EXO_{si-LNMAT2#1}, or 5637-EXO_{si-LNMAT2#2} (G). Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests for multiple comparisons. (H) qRT-PCR confirming the *LNMAT2* knockout. Statistical significance was assessed using 2-tailed Student's *t* test. Representative images (I) and quantification of tube formation (J) and Transwell migration (K) by HLECs (*LNMAT2*-KO or *LNMAT2*-WT) after treating with 5637-EXO_{si-NC} or 5637-EXO_{si-LNMAT2#1}. Scale bars: 100 μ m. Statistical significance was assessed using 2-tailed Student's *t* test. *GAPDH* was used as an internal control for qRT-PCR analysis in A–H. Error bars represent the SD of 3 independent experiments. **P* < 0.05; ***P* < 0.01.




Figure 8. Exosomal *LNMAT2* forms a DNA-RNA triplex with the *PROX1* promoter. qRT-PCR (A) and Western blot (B) of *PROX1* expression in HLECs treated with PBS, 5637-EXO_{Vector}, or 5637-EXO_{LNMAT2}. *GAPDH* was used as an internal control in qRT-PCR. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (C) Sequential deletions for evaluating the transcriptional activity of the *PROX1* promoter in HLECs treated with 5637-EXO_{Vector} or 5637-EXO_{LNMAT2}. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (D) Schematic presentation of the predicted *LNMAT2* binding sites in the *PROX1* promoter. (E) ChIP of *LNMAT2*-associated chromatin in HLECs treated with 5637-EXO. Statistical significance was assessed using 2-tailed Student's *t* test. (F) ChIP of *LNMAT2*-associated chromatin in *LNMAT2*-WT or *LNMAT2*-KO HLECs treated with 5637-EXO. Statistical significance was assessed using 2-tailed Student's *t* test. (G) FRET of a 1:5 mixture (red) of TFO (black) in *LNMAT2* with TTS (blue) in the *PROX1* promoter. (H) CD spectrum of a 1:1 mixture of TFO in *LNMAT2* with TTS in the *PROX1* promoter (red). The sum of the TFO and TTS is shown in blue. Evaluation of WT or *LNMAT2* binding site mutated *PROX1* promoter in *LNMAT2*-WT (I) or *LNMAT2*-KO (J) HLECs, respectively, treated with 5637-EXO_{Vector} or 5637-EXO_{LNMAT2}. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. ChIP-qPCR of hnRNP A2B1 occupancy (K and M) and H3K4me3 (L and N) status in the *PROX1* promoter after HLEC incubation with indicated exosomes. Statistical significance was assessed using 2-tailed Student's *t* test and 1-way ANOVA followed by Dunnett's tests for multiple comparisons. Error bars represent the SD of 3 independent experiments. *P < 0.05; **P < 0.01.

significance of exosomal *LNMAT2* in BCa LN metastasis would be of great significance. First, we found that *LNMAT2* overexpression was associated with increased lymphatic vessel density in both the intratumoral and peritumoral regions of BCa tissues in another

206-case cohort (Figure 10, A and B). Interestingly, *LNMAT2* expression in urinary-EXO correlated positively with that in paired tumor tissues (Supplemental Figure 11A). Consistently, ISH showed significantly upregulated *LNMAT2* expression in tumor tis-




Figure 9. PROX1 is required for exosomal *LNMT2*-mediated lymphangiogenesis. Representative images (A) and histogram analysis of tube formation (B) and Transwell migration (C) by *LNMT2*-KO HLECs treated with 5637-EXO_{si-NC} or 5637-EXO_{si-LNMT2#1} transfected with vector or *PROX1* plasmid, or in which VEGF-C was inhibited. Scale bars: 100 μ m. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. Representative bioluminescence images (D) and histogram analysis (E) of popliteal metastatic LN from nude mice treated with PBS, UM-UC-3-EXO_{Vector}, or UM-UC-3-EXO_{LNMT2} with or without coinjection of VEGF-C neutralizing antibody after UM-UC-3 cells had been inoculated into the footpad ($n = 16$). Red arrow indicates footpad tumor and metastatic popliteal LN. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. (F) Histogram analysis of the LN volume ($n = 16$). Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests. Representative images (G) and histogram analysis of IHC staining evaluating lymphatic vessel density based on LYVE-1 (H) and *PROX1* expression (I) in footpad tumors ($n = 16$). Scale bars: 50 μ m. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests and the χ^2 test. (J) The percentages of LN status in all groups ($n = 16$). Statistical significance was assessed by χ^2 test. (K) Kaplan-Meier survival curve for control, UM-UC-3-EXO_{Vector}, or UM-UC-3-EXO_{LNMT2} groups with or without inhibition of VEGF-C ($n = 16$). Error bars represent the SD of 3 independent experiments. * $P < 0.05$; ** $P < 0.01$.

sues from BCa patients with high exosomal *LNMT2* as compared with patients with low exosomal *LNMT2* (Supplemental Figure 11, B and C), implying that exosomal *LNMT2* played a crucial role in *LNMT2*-related LN metastasis in BCa. We explored whether exosomal *LNMT2* was clinically relevant to LN metastasis in BCa. Exosomal *LNMT2* expression in BCa patients with LN metastasis was dramatically higher than that in patients without LN metastasis (Figure 10C). Statistical analysis revealed a positive correlation between exosomal *LNMT2* and LN metastasis (Supplemental Table 7). Moreover, Kaplan-Meier analysis showed that high exosomal *LNMT2* level was associated with poor prognosis of BCa (Figure 10, D and E). Univariate and multivariate analysis also supported exosomal *LNMT2* as an independent prognostic factor of OS and DFS in BCa (Supplemental Tables 8 and 9). Receiver operating characteristic (ROC) analysis showed that urinary exosomal *LNMT2* could discriminate between patients with BCa and the healthy controls, and there was higher diagnostic accuracy, as measured by the AUC, for diagnosing LN metastasis in BCa (Figure 10, F and G). Consistently, we also found that exosomal *LNMT2* was significantly elevated in BCa serum samples, and higher *LNMT2* expression was detected in serum exosomes (serum-EXO) from BCa patients with LN metastasis compared with that from patients without LN metastasis (Supplemental Figure 11, D and E). Importantly, serum exosomal *LNMT2* overexpression correlated with shorter OS in BCa patients (Supplemental Figure 11F). Taken together, our results suggest that exosomal *LNMT2* might be a potential diagnostic biomarker and therapeutic target for LN metastatic BCa (Figure 10H).

Discussion

Lymphangiogenesis, the growth of new lymphatic vessels, plays a crucial part in LN metastasis (38). Although tumor-associated lymphangiogenesis is driven mainly by VEGF-C, nearly 20% of BCa with LN metastasis show low VEGF-C expression (5, 6). So far, the mechanism of lymphatic metastasis of BCa cells with low

VEGF-C expression remains unknown. Herein, we demonstrated that a tumor-secreted exosomal lncRNA is involved in lymphangiogenesis and LN metastasis of BCa in a VEGF-C-independent manner. We identified a novel lncRNA, *LNMT2*, which is enriched in urinary exosomes and plays an important role in BCa lymphatic metastasis. *LNMT2* was packaged into exosomes via direct interaction with hnRNP2B1. Subsequently, exosomal *LNMT2* was internalized by HLECs and epigenetically activated *PROX1* expression by recruiting hnRNP2B1 to the *PROX1* promoter, resulting in the lymphangiogenesis and lymphatic metastasis of BCa. These findings provide in-depth mechanistic and translational insights into the pathway by which exosomal lncRNA promotes BCa lymphatic metastasis in a VEGF-C-independent manner, and support the emergence of *LNMT2* as a novel therapeutic target in BCa.

Exosomes have been extensively studied for their function in intercellular communication between the tumor and the tumor microenvironment (TME) (12). Previously, several independent studies have suggested that exosomal lncRNAs were involved in proliferation (39), chemoresistance (40), and stemness (41) in various cancers. Herein, we found that *LNMT2* was overexpressed in urinary-EXO and serum-EXO from patients with BCa, and both urinary and serum exosomal *LNMT2* were positively associated with lymphatic metastasis in patients with BCa, which indicated that exosomal RNA analysis could be utilized for early detection of LN metastasis. Our results showed that exosomal *LNMT2* promoted lymphangiogenesis and LN metastasis of BCa, suggesting that *LNMT2* may represent a potential molecular target for clinical intervention in patients with BCa with LN metastasis.

It is well-established that LN metastasis is a major cause of BCa-related mortality, and intervention of LN metastasis might be a promising therapeutic strategy for improving the prognosis of BCa (42, 43). Herein, a tumor-secreted exosomal *LNMT2* emerged as a potent target for diminishing lymphangiogenesis and LN metastasis in BCa, highlighting its attractive role in cancer treatment. We demonstrated that downregulating exosomal *LNMT2* expression in BCa cells via RNA interference inhibited tumor-associated lymphangiogenesis and might be a potential approach for suppressing LN metastasis. However, the stabilization and delivery efficiency of siRNAs in vivo is one of the most critical issues in oligonucleotide therapeutics. Locked nucleic acid (LNA) modification improved siRNA stability and pharmacokinetics, and could be exploited to facilitate siRNA delivery into target cells, resulting in effective suppression of tumor growth with minimal adverse effects in experimental animal models (44). Therefore, inhibiting the function of exosomal *LNMT2* via LNA-modified siRNA might develop a new strategy for treating LN metastasis in human cancer.

Exosomes regulate the biological functions of recipient cells via RNA transfer. The exosomal RNAs are selectively sorted into exosomes by several RBPs (29, 30), including hnRNP2B1, which participates in exosomal RNA packaging by interacting with its target RNAs (29). It has been demonstrated that hnRNP2B1 regulates the localization of miRNA into exosomes by binding to specific motifs (i.e., GGAG) (29). hnRNP2B1 also plays a role in loading a lncRNA (*lncARSR*) into exosomes (45). In the present study, we proposed a model wherein hnRNP2B1 binds specif-




Figure 10. Exosomal *LNMAT2* is associated with BCa lymphatic metastasis. Representative images (**A**) and percentages (**B**) of BCa tissues ($n = 206$) with high and low LYVE-1 levels in the intratumoral and peritumoral lymphatic vessels in patients with different expression of *LNMAT2*. Scale bars: 50 μ m. Statistical significance was assessed by χ^2 test. (**C**) qRT-PCR analysis of *LNMAT2* expression in a 206-patient cohort of urinary-EXO from BCa patients with or without LN metastasis. *GAPDH* was used as an internal control. Groups were compared using the nonparametric Mann-Whitney *U* test. Kaplan-Meier curves of OS (**D**) and DFS (**E**) of patients with BCa according to the relative urinary exosomal *LNMAT2* expression. The median expression was used as the cut-off value ($n = 206$). ROC curve analyses for evaluating the diagnostic potential of urinary exosomal *LNMAT2* for BCa (**F**) and LN metastasis (**G**). (**H**) Proposed model of BCa cell-secreted exosomal *LNMAT2*-mediated PROX1 activation in HLECs for promoting lymphangiogenesis and LN metastasis. * $P < 0.05$; ** $P < 0.01$.

ically to *LNMT2* through a specific sequence on 1930–1960 nt of *LNMT2* and directs its packaging into exosomes. The identification of hnRNPA2B1 for exporting *LNMT2* in exosomes may provide unique strategies for eliminating *LNMT2* in the TME and for blocking exosomal *LNMT2*-mediated BCa LN metastasis.

Another important finding in the present study was that cancer-secreted exosomal *LNMT2* upregulated *PROX1* expression epigenetically in HLECs. *PROX1* is the key transcription factor driving HLEC fate and specification by regulating the expression of various lymphatic-specific proteins, including VEGFR3, LYVE-1, and podoplanin (9, 46). *PROX1* overexpression controls lymphangiogenesis by inducing HLEC proliferation and migration (47, 48). Importantly, *PROX1* depletion in mouse models causes lymphatic defects that lead to mortality (9). Although several studies have indicated the essential role of *PROX1* in lymphangiogenesis, cancer-induced *PROX1* transcription in HLECs remains unknown. Herein, we demonstrated that BCa cell-secreted exosomal *LNMT2* upregulated *PROX1* expression in HLECs by forming a DNA-RNA triplex with the binding site of the *PROX1* promoter. *PROX1* downregulation abolished the prolymphangiogenesis effect induced by exosomal *LNMT2*. Our findings uncovered what we believe is a novel molecular mechanism underlying the cancer-secreted exosomal lncRNA-mediated *PROX1* overexpression in HLECs, resulting in lymphangiogenesis and LN metastasis, which expanded the current knowledge on *PROX1* regulation in HLECs.

In summary, our findings provided evidence of a VEGF-C-independent LN metastasis mechanism in which BCa cell-secreted exosomal *LNMT2* promoted lymphangiogenesis and LN metastasis by transcriptionally upregulating *PROX1* in HLECs. We also found that *LNMT2* was overexpressed in both the urinary-EXO and serum-EXO of BCa patients, which positively correlated with both intratumoral and peritumoral lymphangiogenesis, and was clinically relevant to BCa LN metastasis. Our study not only identifies a crucial mechanism of exosomal lncRNA-mediated intercellular communication from BCa cells to the TME to provoke LN metastasis, but also develops a potential noninvasive diagnostic approach and therapeutic strategy for patients with BCa with LN metastasis.

Methods

Clinical samples and study approval. A total of 266 pairs of tumor tissues and NATs from patients with BCa who underwent surgery was obtained at Sun Yat-sen Memorial Hospital (Cohort 1). Urine and blood samples were obtained from another 206 patients with BCa and 120 healthy participants (Cohort 2). In both cohorts, patients were eligible if they had pathologically confirmed BCa. The clinical features of the patients are summarized in Supplemental Table 1 and Supplemental Table 7. All experiments were conducted with the approval of the Committees for Ethical Review of Research involving Human Subjects at Sun Yat-sen University. Written informed consent was obtained from all participants prior to sample collection.

Cell lines and cell culture. The human BCa cell lines UM-UC-3 (CRL-1749), 5637 (HTB-9), and T24 (HTB-4), and the immortalized normal human urothelial cell line SV-HUC-1 (CRL-9520) were purchased from American Type Culture Collection. UM-UC-3 and T24 cells were cultured in DMEM (Gibco) supplemented with 10% FBS. The 5637 and SV-HUC-1 cells were cultured in RPMI 1640 medium

(Gibco) supplemented with 10% FBS and F-12K medium (HyClone) supplemented with 10% FBS, respectively. HLECs (catalog 2500) were purchased from ScienCell Research Laboratories and cultured in endothelial cell medium (ECM) (ScienCell Research Laboratories) supplemented with 5% FBS. The cells were cultured in a humidified incubator with 5% CO₂ at 37°C.

Mouse popliteal lymphatic metastasis model. BALB/c nude mice (4–5 weeks old, 18–20 g) were purchased from the Experimental Animal Center, Sun Yat-sen University (Guangzhou, China) and were used for the lymphatic metastasis model. All experimental procedures were conducted with the approval of the Sun Yat-sen University IACUC. Luciferase-labeled UM-UC-3 cells (5×10^6) were inoculated into the footpads of the mice. Then, the mice were randomly divided into 3 groups ($n = 12$ or 16 per group) and injected intratumorally with PBS, UM-UC-3-EXO_{Vector}, or UM-UC-3-EXO_{LNMT2} (20 µg/dose) every 3 days. Lymphatic metastasis was analyzed using a PerkinElmer IVIS Spectrum In Vivo Imaging System. The footpad tumors and popliteal LNs were excised when the tumors were 200 mm³ (LN volume (mm³) = (length [mm] × width [mm]²) / 2). Serial sections of primary tumors and popliteal LNs were analyzed by ISH and IHC. The sections were visualized with a Nikon Eclipse Ti microscope. For survival analysis, the mice were observed until death or were sacrificed by cervical dislocation 80 days after the first injection of PBS or exosomes.

RNA pull-down and RIP assays. The *LNMT2*-binding proteins were examined using RNA pull-down assays according to the instructions of the Pierce Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scientific). Biotinylated *LNMT2* and antisense sequences were synthesized using a TranscriptAid T7 High Yield Transcription Kit (Thermo Fisher Scientific). The nuclear fraction obtained using a NE-PER Nuclear Protein Extraction Kit (Thermo Fisher Scientific) was incubated overnight with biotinylated *LNMT2*, followed by precipitation with streptavidin magnetic beads. The retrieved protein was eluted from the RNA-protein complex and analyzed by immunoblotting or silver staining, followed by MS analysis with a MALDI-TOF instrument (Bruker Daltonics).

The RIP assays were performed using an EZ-Magna RIP kit (Millipore). Lysates of 1×10^7 BCa cells obtained using complete RIP lysis buffer were immunoprecipitated with RIP buffer containing anti-hnRNPA2B1 antibody-conjugated magnetic beads (Abcam). The precipitated RNAs were analyzed by qRT-PCR. Mouse IgG and U1 RNA were used as the negative and nonspecific controls, respectively.

FRET and CD spectroscopy. For FRET assays, 5-carboxytetramethylrhodamine-labeled (TAMRA-labeled) TFO and 5-carboxyfluorescein-labeled (FAM-labeled) TTSs were generated and mixed in binding buffer (20 mM HEPES [pH 7.5], 10 mM MgCl₂, 50 mM sodium acetate) in a ratio of 1:5 (500 nM TTS/2500 nM TFO). The mixtures were incubated at 55°C for 10 minutes, followed by a 10-hour incubation at 37°C. The fluorescence wavelengths between 480 and 690 nm were measured using a Molecular Device M5 Plate Reader.

For the CD spectroscopy, a 1:1 mixture of TFO (2.2 µM) and TTS oligos (2.2 µM) in binding buffer (20 mM HEPES [pH 7.5], 10 mM MgCl₂, 50 mM sodium acetate) was equilibrated at 30°C for 1 hour. Control ssRNA/*PROX1* TTS and *FENDRR* TFO/*PITX2* TTS were used as the negative and positive controls, respectively. The measurements were performed on a Chirascan spectrometer (Applied Photophysics). The oligos used in the FRET and CD spectroscopy are listed in Supplemental Table 5.

Data availability. The NGS data for this study (GSE106534, GSE106637) are available on the National Center for Biotechnology Information website (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106534>). All relevant data within the scope of the paper are publicly available.

Bioinformatics analysis. The hnRNA2B1 binding motif enrichment in RNAs was obtained via POSTAR2. The *LNMT2* secondary structure was predicted using RNAalifold. The *LNMT2* binding motifs in the *PROX1* promoter and the binding sequences in *LNMT2* were predicted by LongTarget.

Statistics. Statistical differences between groups were evaluated using SPSS v.13.0 (SPSS Inc.). Data were considered statistically significant if *P* was less than 0.05. All experiments were performed in triplicate, and quantitative data are presented as the mean $\pm$ SD. Statistical significance for samples with nonnormal distribution was identified using the Mann-Whitney *U* test, 2-tailed Student's *t* test or 1-way ANOVA was applied for parametric variables, and the χ^2 test was applied for nonparametric variables. OS and DFS were evaluated using the Kaplan-Meier method.

Study approval. The use of human BCa tissue specimens was evaluated and approved by the Ethical Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, and written informed consent was obtained from all participants or their appropriate surrogates. All animal studies were conducted with approval from the Sun Yat-sen University Institutional Animal Care and Use Committee and were performed in accordance with established guidelines.

Author contributions

CC, JH, RC, and TL conceived, designed, and directed the study. Y Li, Y Luo, WH, and YZ performed the in vitro and in vivo experiments and data analyses. YK, YZ, and HL performed the clinical data analyses. WH and GZ performed the ISH and IHC experiments. CC, JL, and Y Luo wrote and critically reviewed the man-

uscript. All authors read and approved the final manuscript. The order of the co-first authors was assigned based on the relative contributions of these individuals.

Acknowledgments

The authors thank JX Zhang of the Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, for statistical advice and research comments. This study was funded by the National Key Research and Development Program of China (grant no. 2018YFA0902803); the National Natural Science Foundation of China (grant nos. 81825016, 81802530, 81830082, 81772719, 81772728, 91740119); Guangdong Medical Research Foundation (grant no. A2018330); Medical Scientific Research Foundation of Guangdong Province (grant no. A201947); Science and Technology Program of Guangzhou (grant nos. 201604020156, 201604020177, 201707010116, 2017B020227007); National Natural Science Foundation of Guangdong (grant nos. 2018A030313564, 2018A030310250, 2016A030313321); Yixian Youth project of Sun Yat-sen Memorial Hospital (grant no. YXQH201812); The Key Areas Research and Development Program of Guangdong (grant no. 2018B010109006); Guangdong Province Higher Vocational Colleges & Schools Pearl River Scholar Funded Scheme (to TL).

Address correspondence to: Tianxin Lin and Jian Huang, Department of Urology, Sun Yat-sen Memorial Hospital, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong, 510120, China. Phone: 86.20.34070447; Email: lintx@mail.sysu.edu.cn, urol-hj@sina.com. Or to: Rufu Chen, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, China. Phone: 86.20.18922182828; Email: chenrf63@163.com.

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424.
- Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. *Eur Urol.* 2012;61(5):1039–1047.
- He W, et al. Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis. *J Clin Invest.* 2018;128(2):861–875.
- Chen C, et al. LNMT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. *Nat Commun.* 2018;9(1):3826.
- Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. *BJU Int.* 2006;98(5):1090–1093.
- Suzuki K, Morita T, Tokue A. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. *Int J Urol.* 2005;12(2):152–158.
- Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. *Trends Immunol.* 2004;25(7):387–395.
- Plate K. From angiogenesis to lymphangiogenesis. *Nat Med.* 2001;7(2):151–152.
- Wigle JT, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. *EMBO J.* 2002;21(7):1505–1513.
- Flister MJ, et al. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. *Blood.* 2010;115(2):418–429.
- Zhang ZG, Buller B, Chopp M. Exosomes - beyond stem cells for restorative therapy in stroke and neurological injury. *Nat Rev Neurol.* 2019;15(4):193–203.
- Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer - implications for future improvements in cancer care. *Nat Rev Clin Oncol.* 2018;15(10):617–638.
- Fang JH, et al. Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. *Hepatology.* 2018;68(4):1459–1475.
- Pan Y, et al. Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation. *J Clin Invest.* 2019;129(2):834–849.
- Cheng M, et al. Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells. *Nat Commun.* 2019;10(1):959.
- Zhang H, et al. Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. *Nat Commun.* 2017;8:15016.
- Zeng Z, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. *Nat Commun.* 2018;9(1):5395.
- Fang T, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. *Nat Commun.* 2018;9(1):191.
- Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. *Nat Cell Biol.* 2019;21(1):9–17.
- Ji H, et al. TNFR1 mediates TNF- α -induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. *Nat Commun.* 2014;5:4944.
- Chen F, et al. Extracellular vesicle-packaged

- HIF-1 α -stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. *Nat Cell Biol.* 2019;21(4):498–510.
22. Karaman S, Detmar M. Mechanisms of lymphatic metastasis. *J Clin Invest.* 2014;124(3):922–928.
 23. Seok Y, et al. Frequency of lymph node metastasis according to the size of tumors in resected pulmonary adenocarcinoma with a size of 30 mm or smaller. *J Thorac Oncol.* 2014;9(6):818–824.
 24. Liu YY, et al. Does a higher cutoff value of lymph node retrieval substantially improve survival in patients with advanced gastric cancer?—time to embrace a new digit. *Oncologist.* 2017;22(1):97–106.
 25. Rault-Petit B, et al. Current management and predictive factors of lymph node metastasis of appendix neuroendocrine tumors: a national study from the french group of endocrine tumors (GTE). *Ann Surg.* 2019;270(1):165–171.
 26. Moran-Jones K, et al. hnRNP A2, a potential ssDNA/RNA molecular adapter at the telomere. *Nucleic Acids Res.* 2005;33(2):486–496.
 27. Zhu Y, et al. POSTAR2: deciphering the post-transcriptional regulatory logics. *Nucleic Acids Res.* 2019;47(D1):D203–D211.
 28. Hu B, Yang YT, Huang Y, Zhu Y, Lu ZJ. POSTAR: a platform for exploring post-transcriptional regulation coordinated by RNA-binding proteins. *Nucleic Acids Res.* 2017;45(D1):D104–D114.
 29. Villarroya-Beltri C, et al. Sumoylated hnRNP A2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. *Nat Commun.* 2013;4:2980.
 30. Shurtleff MJ, Temoche-Diaz MM, Karfilis KV, Ri S, Schekman R. Y-box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction. *Elife.* 2016;5:e19276.
 31. Park KJ, et al. Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis. *Gastric Cancer.* 2017;20(1):104–115.
 32. Cho H, et al. YAP and TAZ negatively regulate Prox1 during developmental and pathologic lymphangiogenesis. *Circ Res.* 2019;124(2):225–242.
 33. He S, Zhang H, Liu H, Zhu H. LongTarget: a tool to predict lncRNA DNA-binding motifs and binding sites via Hoogsteen base-pairing analysis. *Bioinformatics.* 2015;31(2):178–186.
 34. Grote P, Herrmann BG. The long non-coding RNA Fendrr links epigenetic control mechanisms to gene regulatory networks in mammalian embryogenesis. *RNA Biol.* 2013;10(10):1579–1585.
 35. Tchurikov NA, et al. Hot spots of DNA double-strand breaks and genomic contacts of human rDNA units are involved in epigenetic regulation. *J Mol Cell Biol.* 2015;7(4):366–382.
 36. Tchurikov NA, et al. DNA double-strand breaks coupled with PARP1 and HNRNPA2B1 binding sites flank coordinately expressed domains in human chromosomes. *PLoS Genet.* 2013;9(4):e1003429.
 37. Zhan Y, et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. *Mol Cancer.* 2018;17(1):142.
 38. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. *Nature.* 2005;438(7070):946–953.
 39. Xue M, et al. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1. *Mol Cancer.* 2017;16(1):143.
 40. Xu H, et al. Exosome-transmitted PSMA3 and PSMA3-AS1 promote proteasome inhibitor resistance in multiple myeloma. *Clin Cancer Res.* 2019;25(6):1923–1935.
 41. Ren J, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. *Theranostics.* 2018;8(14):3932–3948.
 42. Fernández MI, et al. Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. *Eur Urol.* 2008;53(3):571–578.
 43. Kluth LA, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. *Eur Urol.* 2015;68(2):238–253.
 44. Fluiter K, Mook OR, Baas F. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence. *Methods Mol Biol.* 2009;487:189–203.
 45. Qu L, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. *Cancer Cell.* 2016;29(5):653–668.
 46. Lee S, et al. Prox1 physically and functionally interacts with COUP-TFII to specify lymphatic endothelial cell fate. *Blood.* 2009;113(8):1856–1859.
 47. Cha B, et al. Complementary Wnt sources regulate lymphatic vascular development via PROX1-dependent Wnt/ β -catenin signaling. *Cell Rep.* 2018;25(3):571–584.e5.
 48. Wong BW, et al. The role of fatty acid β -oxidation in lymphangiogenesis. *Nature.* 2017;542(7639):49–54.